STOCK TITAN

Buxton Helmsley Issues Letter to Endo International Plc. Shareholders and Creditors, Relating to Corporate Malfeasance and False Statements of Financials

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

NEW YORK--(BUSINESS WIRE)-- The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, “BHG” or “we”), the New York City-based investment advisor to clients with financial interests in Endo International Plc. (“Endo” or the “Company”) (NASDAQ: ENDP), today issued an open letter to shareholders and creditors of the Company, relating to corporate malfeasance and false statements of financial position.

The full open letter to the Company’s shareholders and creditors, along with the private letters between BHG and the Company leading up to this open letter, may be found at: http://www.exposingendo.com/

Members of the Endo International Plc. Board of Directors: Mark G. Barberio, Jennifer M. Chao, Blaise Coleman, Shane M. Cooke, Nancy J. Hutson (Ph.D.), Michael Hyatt, William P. Montague, and M. Christine Smith (Ph.D.).

About Buxton Helmsley: The Buxton Helmsley Group, Inc. ("BHG") is a premier financial service, asset management and securities research firm, providing an array of services to a diversified group of individuals, corporations, trusts and other entities. The firm is headquartered in New York City.

Media:

Public Relations and Corp. Comm.

The Buxton Helmsley Group, Inc.

+1 (212) 561 - 5540, Option 4

press@buxtonhelmsley.com

Source: The Buxton Helmsley Group, Inc.

Endo International plc

NASDAQ:ENDP

ENDP Rankings

ENDP Latest News

ENDP Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing

About ENDP

Endo is a specialty pharmaceutical company committed to helping everyone it serves live their best life through the delivery of quality, life-enhancing therapies. Its decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, it boldly transforms insights into treatments benefiting those who need them, when they need them.